Letters to the Editor

In vivo efficacy of the novel anti-microtubule inhibitor E7130 in preclinical models of early T-cell precursor acute lymphoblastic leukemia

Children’s Cancer Institute at Minderoo Children’s Comprehensive Cancer Centre, Sydney, NSW, Australia; School of Clinical Medicine, UNSW Sydney, Sydney, NSW
Children’s Cancer Institute at Minderoo Children’s Comprehensive Cancer Centre, Sydney, NSW, Australia; School of Clinical Medicine, UNSW Sydney, Sydney, NSW
Children’s Cancer Institute at Minderoo Children’s Comprehensive Cancer Centre, Sydney, NSW, Australia; School of Clinical Medicine, UNSW Sydney, Sydney, NSW
Children’s Cancer Institute at Minderoo Children’s Comprehensive Cancer Centre, Sydney, NSW, Australia; School of Clinical Medicine, UNSW Sydney, Sydney, NSW
Children’s Cancer Institute at Minderoo Children’s Comprehensive Cancer Centre, Sydney, NSW, Australia; School of Clinical Medicine, UNSW Sydney, Sydney, NSW
Children’s Cancer Institute at Minderoo Children’s Comprehensive Cancer Centre, Sydney, NSW, Australia; School of Clinical Medicine, UNSW Sydney, Sydney, NSW
RTI International, Research Triangle Park, NC
RTI International, Research Triangle Park, NC
The Jackson Laboratory, Sacramento, CA
The Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME
National Cancer Institute, Bethesda, MD
National Cancer Institute, Bethesda, MD
Children’s Cancer Institute at Minderoo Children’s Comprehensive Cancer Centre, Sydney, NSW, Australia; School of Clinical Medicine, UNSW Sydney, Sydney, NSW
Haematologica Early view Oct 22, 2026 https://doi.org/10.3324/haematol.2026.301211